Cisplatin-based chemotherapy (CBCT) in testicular cancer (TC) is associated with elevated venous thromboembolism (VTE) risk, but trials evaluating the safety and efficacy of thromboprophylaxis are lacking.
Cabozantinib, a potent multityrosine kinases inhibitor (TKI), has demonstrated overall survival (OS) benefit over everolimus in patients previously treated with VEGFR TKI for metastatic Renal Cell Carcinoma (mRCC).
Immune checkpoint-inhibitor (ICI)-based therapy is the standard of care for first-line treatment of metastatic renal cell carcinoma (mRCC). It is unclear whether prior removal of the primary tumor influences the efficacy of these treatments.
Prostate cancer pathological nodal staging uses a single category for all node-positive patients. We sought to improve risk stratification by creating and validating a novel pathological nodal staging system incorporating number of metastatic lymph nodes (+LNs).
Multiparametric MRI (mpMRI) fails to identify some men with significant prostate cancer. PSMA PET/CT is recommended for staging of prostate cancer, but its additional benefit above mpMRI alone in local evaluation for prostate cancer is unclear.
The use of prostate fiducial markers and perirectal hydrogel spacers can reduce the acute and late toxicities associated with prostate radiotherapy. These procedures are usually performed days-to-weeks before simulation as a separate clinic visit to ensure resolution of procedure-related inflammation.
There are limited data regarding the effect of treatment delays on important long-term outcomes among men with intermediate-/high-risk prostate cancer (PC). We identified 3,962 men with intermediate-/high-risk disease from the SEARCH cohort treated with radical prostatectomy (RP) from 1988-2018.
To evaluate the conditional intravesical recurrence (IVR)-free (IVRF) survival rate in patients with upper tract urothelial carcinoma (UTUC) who had no history of bladder cancer and no concomitant bladder cancer.
"MK," a man aged 67 years, presented with fatigue and nausea to his primary care physician. Routine blood tests showed a stage III acute kidney injury and the patient was admitted urgently into the hospital for investigation.
While lymph node dissection (LND) at radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) has been studied extensively, the role of LND for non-muscle invasive bladder cancer (NMIBC) remains incompletely defined.
